Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients

    NEXT STORY
    COVID-19 Impact on Social and Emotional Learning (SEL) Market – Global Forecast to 2026
    PREV STORY
    Ascendis Pharma A/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Vical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common Stock

    SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the ...

    author_avatar
    NASDAQ Market News

    Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

    author_avatar
    NASDAQ Market News

    Valneva Confirms Delisting from the Vienna Stock Exchange

    author_avatar
    NASDAQ Market News